Research programme: anticancer prodrug therapeutics - HC Biopharma
Latest Information Update: 27 Aug 2024
Price :
$50 *
At a glance
- Originator HC Biopharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 27 Aug 2024 Research programme: anticancer prodrug therapeutics - HC Biopharma is available for licensing as of 27 Aug 2024. http://www.hcbiopharma.com/en/
- 27 Aug 2024 Preclinical trials in Solid tumours in Hong Kong (unspecified route) (HC Biopharma pipeline, August 2024)
- 02 Aug 2024 Early research in Solid tumours in Hong Kong (unspecified route) (HC Biopharma Pipeline, August 2024)